June 2021
Volume 62, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2021
M-CHARTS evaluation and comparison of two Aflibercept regimens for neovascular age-related macular degeneration
Author Affiliations & Notes
  • Marion Schroeder
    Lunds Universitet, Lund, Sweden
  • Monica K Loevestam-Adrian
    Lunds Universitet, Lund, Sweden
  • Footnotes
    Commercial Relationships   Marion Schroeder, Bayer Pharma AG (F), Bayer Pharma AG (R); Monica K Loevestam-Adrian, Allergan (C), Bayer Pharma AG (F), Bayer Pharma AG (C), Novartis (C), Santen (C)
  • Footnotes
    Support  Bayer Pharma AG
Investigative Ophthalmology & Visual Science June 2021, Vol.62, 306. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Marion Schroeder, Monica K Loevestam-Adrian; M-CHARTS evaluation and comparison of two Aflibercept regimens for neovascular age-related macular degeneration. Invest. Ophthalmol. Vis. Sci. 2021;62(8):306.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To compare multiple functional and physiological outcomes with M-CHARTS values in patients treated with aflibercept for neovascular age-related macular degeneration (nAMD) in two arms, label vs treat-and-extend (TAE).

Methods : This prospective study randomized 41 eyes of 41 treatment-naïve patients with nAMD to two regimens. Arm 1 was treated with aflibercept according to label with three monthly injections, followed by bimonthly injections to the end of year one, thereafter the regimen changed to TAE. Arm 2 received the TAE regimen over the total study period of 18 months. Number of injections, best-corrected visual acuity (VA), near visual acuity (NVA), full-field and multifocal electroretinography (ffERG, mERG), optical coherence tomography (OCT) had been presented in a previous report. The present study evaluated M-CHARTS variables, including a questionnaire, horizontal metamorphopsia (MH), vertical metamorphopsia (MV), and vision-related quality of life (QoL) with the National Eye Institute Visual Function Questionnaire (NEI-VFQ-25).

Results : In arm 1, 19 eyes presented with available baseline and follow-up data for M-CHARTS values, 18 eyes in arm 2. From baseline to the final follow-up, the MV score improved significantly in arm 1 from .65±.53 to .44±.53; p=.029, and in arm 2 from .49±.48 to .20±.29; p=.007. The MH score showed significant improvements in arm 1 from .74±.55 to .41±.51; p=.028, but no significant changes in arm 2 from .64±.63 to .33±.48; p=.075. The M-CHARTS questionnaire score showed decreased subjective perception of metamorphopsia in arm 1 from 1.79±.85 to 1.58±.69; p=.331; in arm 2 from 2.17±.78 to 1.56±.784; p=.022. During the 18 months, we found no significant correlation between changes of MV, MH or M-CHARTS questionnaire results and changes of VA, NVA, ffERG, mERG, and QoL composite score. When comparing the mean change of variables over time and between regimens, we only found a statistically significant difference between the two arms in two vision-related subgroups of the NEI-VFQ-25, general vision; p=.001, and near activities; p=.012.

Conclusions : MV emerged as statistically significant variable to follow-up and quantify metamorphopsia. As earlier described, M-CHARTS variables presented as independent parameters. The outcomes of the two aflibercept regimens showed no significant differences, besides two vision-related items of the NEI-VFQ-25.

This is a 2021 ARVO Annual Meeting abstract.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×